Table 5. Effect of CP-1, CP-2, and CP-6 on Triton WR-1339-induced hyperlipidemia in rats (VLDL-C and Atherogenic Index).
| Group | 0 hour | 6 hours | 24 hours | 48 hours | ||||
|---|---|---|---|---|---|---|---|---|
| VLDL-C (mg/dl) | Atherogenic Index | VLDL-C (mg/dl) | Atherogenic Index | VLDL-C (mg/dl) | Atherogenic Index | VLDL-C (mg/dl) | Atherogenic Index | |
| G1 | 22.04±1.2 | 0.09±0.001 | 22.5±1.4 | 0.99±0.001 | 22.84±0.9 | 0.07±0.001 | 21.62±1.2 | 0.08±0.001 |
| G2 | 23.12±0.9 | 0.03±0.001 | 96.48±6.7*** | 7.70±0.1*** | 78.84±4.9*** | 2.16±0.2*** | 55.06±3.4** | 1.07±0.01** |
| G3 | 21.68±0.8 | 0.05±0.001 | 47.28±2.8 †† | 3.42±0.01†† | 37.24±1.9†† | 1.33±0.001† | 32.08±1.5† | 0.73±0.01† |
| G4 | 22.56±0.9 | 8.37±0.1 | 38.44±1.4 ††† | 2.66±0.2††† | 34.5±1.2†† | 0.67±0.001†† | 32.48±1.8† | 0.31±0.01†† |
| G5 | 24.04±1.3 | 0.02±0.002 | 41.68±1.6 †† | 3.93±0.3†† | 37.42±1.6†† | 1.56±0.001† | 34.36±1.4† | 0.92±0.01 |
| G6 | 21.94±1.0 | 0.03±0.001 | 34.48±2.0 ††† | 2.16±0.01††† | 31.92±2.4††† | 0.40±0.001††† | 29.74±1.6† | 0.32±0.01†† |
| G7 | 23.58±0.7 | 0.09±0.001 | 37.28±2.1 ††† | 2.66±0.01††† | 34.24±2.1†† | 0.87±0.001†† | 29.42±1.1† | 0.47±0.01†† |
| G8 | 25.32±1.2 | 0.01±0.0001 | 26.28±1.3 ††† | 1.34±0.001††† | 25.64±1.5††† | 0.27±0.001††† | 24.54±1.8†† | 0.08±0.001††† |
| G9 | 22.58±1.3 | 0.01±0.0001 | 24.44±1.2 ††† | 1.27±0.001††† | 24.98±1.2††† | 0.28±0.001††† | 21.88±0.9†† | 0.22±0.01†† |
G1 = Normal control, G2 = Pathogenic control, G3 = CP-1 -25 mg/kg p.o, G4 = CP-1 -50 mg/kg p.o, G5 = CP-2 -25 mg/kg p.o, G6 = CP-2 -50 mg/kg p.o, G7 = CP-6 -25 mg/kg p.o, G8 = CP-6 -50 mg/kg p.o, G9 = Atorvastatin -10 mg/kg p.o.
The values are expressed as Mean±SEM, (n=8).* Pathogenic control vs. Normal control (***p<0.001), † Treatments vs. Pathogenic control († p<0.05, †† p<0.01, ††† p<0.001).